We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

235 hedge funds and large institutions have $3.22B invested in Array Biopharma Inc in 2018 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 83 increasing their positions, 62 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

230% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 20

46% more call options, than puts

Call options by funds: $27.3M | Put options by funds: $18.7M

34% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 62

26% more capital invested

Capital invested by funds: $2.56B → $3.22B (+$660M)

23% more funds holding

Funds holding: 191 → 235 (+44)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

Holders
235
Holders Change
+44
Holders Change %
+23.04%
% of All Funds
5.39%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
66
Increased
83
Reduced
62
Closed
20
Calls
$27.3M
Puts
$18.7M
Net Calls
+$8.62M
Net Calls Change
-$12.9M

Top Buyers

1
FCM
Farallon Capital Management
California
+$49.6M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$39.5M
3
American Century Companies
American Century Companies
Missouri
+$25.4M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$22.8M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
+$19.6M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$84.3M
2
BI
BVF Inc
California
-$58M
3
ACA
Avoro Capital Advisors
New York
-$56.8M
4
O
OrbiMed
New York
-$43.6M
5
Morgan Stanley
Morgan Stanley
New York
-$33.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
CEP
126
Chicago Equity Partners
Illinois
$1.64M +$1.61M +100,300 New
State Board of Administration of Florida Retirement System
127
State Board of Administration of Florida Retirement System
Florida
$1.6M +$193K +12,072 +14%
First Trust Advisors
128
First Trust Advisors
Illinois
$1.47M -$775K -48,389 -35%
Jacobs Levy Equity Management
129
Jacobs Levy Equity Management
New Jersey
$1.43M +$607K +37,900 +76%
PNC Financial Services Group
130
PNC Financial Services Group
Pennsylvania
$1.39M +$1.33M +82,787 +3,508%
ACM
131
Asymmetry Capital Management
California
$1.33M +$249K +15,554 +24%
Legal & General Group
132
Legal & General Group
United Kingdom
$1.32M -$370K -23,098 -22%
Russell Investments Group
133
Russell Investments Group
United Kingdom
$1.31M -$1.13M -70,359 -47%
LCG
134
Lisanti Capital Growth
New York
$1.27M +$1.24M +77,610 New
Tudor Investment Corp
135
Tudor Investment Corp
Connecticut
$1.25M +$1.02M +63,473 +495%
Arrowstreet Capital
136
Arrowstreet Capital
Massachusetts
$1.21M +$1.19M +74,219 New
MAP
137
Moody Aldrich Partners
Massachusetts
$1.21M +$1.18M +73,930 New
KIA
138
Kopp Investment Advisors
Minnesota
$1.17M -$658K -41,068 -36%
ECM
139
Endurant Capital Management
California
$1.17M +$333K +20,800 +41%
Hudson Bay Capital Management
140
Hudson Bay Capital Management
Connecticut
$1.14M -$881K -55,000 -44%
NSIM
141
North Star Investment Management
Illinois
$1.14M +$112K +7,000 +11%
MSL
142
Mackay Shields LLC
New York
$1.13M +$1.11M +69,500 New
VEA
143
Virtus ETF Advisers
New York
$1.12M +$587K +36,645 +114%
Victory Capital Management
144
Victory Capital Management
Texas
$1.06M +$993K +62,010 +2,047%
Federated Hermes
145
Federated Hermes
Pennsylvania
$998K +$962K +60,062 +5,445%
SAM
146
Stansberry Asset Management
Texas
$995K +$977K +60,987 New
AR
147
Advisory Research
Illinois
$890K +$874K +54,534 New
DCM
148
Dupont Capital Management
Delaware
$876K – – –
SIM
149
Sonora Investment Management
Arizona
$767K +$30.4K +1,900 +4%
PCM
150
Prelude Capital Management
New York
$755K +$140K +8,758 +23%
4 5
6
7 8

ARRY Hedge Fund Activity: Q1 2018 in Review

235 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2018, worth a combined $3.22B — up 26% from $2.56B a quarter earlier.

Buyers outnumbered sellers: 66 funds opened new ARRY positions and 20 closed out — a net gain of 46 holders — while 83 added to existing stakes and 62 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $49.6M. The largest seller was Point72 Asset Management, cutting an estimated $84.3M.

  • 235 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2018, up from 191 in Q4 2017.
  • Funds reported $3.22B of Array Biopharma Inc stock for Q1 2018, up 26% quarter-over-quarter.
  • 66 funds opened new Array Biopharma Inc positions in Q1 2018 and 20 closed out, a net change of +46 holders.
  • The largest Array Biopharma Inc buyer in Q1 2018 was Farallon Capital Management, an estimated $49.6M added.
  • The largest Array Biopharma Inc seller in Q1 2018 was Point72 Asset Management, an estimated $84.3M sold.

Based on aggregated 13F filings for Q1 2018.